^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    9h
    CHINOREC: Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (clinicaltrials.gov)
    P2, N=80, Completed, Johannes Laengle, MD, PhD | Recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Mar 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine
    10h
    MAMORECT: Magnetomotoric Ultrasound (MMUS) in Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Region Skane | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    11h
    NEAAR-LARC: Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University of South Florida
    New trial • Combination therapy • Metastases
    12h
    Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2) (clinicaltrials.gov)
    P=N/A, N=1686, Suspended, The First Hospital of Jilin University | Recruiting --> Suspended
    Trial suspension • Surgery
    24h
    Early rectal cancer: The diagnostic performance of MRI supplemented with a rectal micro-enema and a modified staging system to identify tumors eligible for local excision. (PubMed, Acta Radiol Open)
    The micro-enema (Bisacodyl) induces submucosal edema and may hypothetically improve the visualization of tumor depth...MRI after a rectal micro-enema and concurrent use of a modified staging system achieved good diagnostic performance to identify tumors suitable for LE. The rate of overstaging of local tumors was comparable to results reported in previous endorectal ultrasound (ERUS) studies.
    Journal
    |
    DERL1 (Derlin 1)
    1d
    Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    Our predictive model, which incorporates TMFP, has considerable accuracy in predicting pCR after nCRT in patients with locally advanced rectal cancer. This may provide a basis for more precisely selecting individualized therapy.
    Journal • Metastases • Biopsy
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    6d
    A Randomized Controlled Trial of the Safety and Efficacy of Robotic Telesurgery Versus Laparoscopic Surgery (clinicaltrials.gov)
    P=N/A, N=177, Not yet recruiting, Sun Yat-sen University
    New trial • Surgery
    7d
    SERENA: Stigma and Psychological profilE in REctal-anal caNcer pAtients (clinicaltrials.gov)
    P=N/A, N=148, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    New trial
    8d
    Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University
    New trial • Metastases
    11d
    Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Case Comprehensive Cancer Center | Not yet recruiting --> Withdrawn | N=30 --> 0
    Enrollment change • Trial withdrawal • Circulating tumor DNA
    |
    Signatera™
    13d
    Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. (PubMed, NPJ Precis Oncol)
    imCMS classification of pre-treatment biopsies is a fast and inexpensive solution to identify patient groups that could benefit from neoadjuvant LCRT. The significant associations between imCMS1/imCMS4 with pCR suggest the existence of predictive morphological features that could enhance standard pathological assessment.
    Journal • Biopsy
    |
    MCM3 (Minichromosome maintenance complex component 3)
    14d
    The prognostic model and immune landscape based on cancer-associated fibroblast features for patients with locally advanced rectal cancer. (PubMed, Heliyon)
    Herein, a nomogram based on CAF features was developed to predict the CSS rate of LARC patients. The risk model was capable of reflecting differences in the level of immune cell infiltration.
    Journal • Metastases
    |
    MAP1B (Microtubule Associated Protein 1B)
    14d
    SHAPERS: Efficacy and Safety of SCRT Versus TNT in Older Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=230, Recruiting, Jules Bordet Institute | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    5-fluorouracil • capecitabine • oxaliplatin
    14d
    CCTG CO.28: NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2024 --> Apr 2024
    Trial primary completion date
    |
    5-fluorouracil
    15d
    Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2) (clinicaltrials.gov)
    P=N/A, N=1686, Recruiting, The First Hospital of Jilin University | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    15d
    Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=54 --> 36 | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Apr 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    15d
    NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=63, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Sep 2024
    Enrollment closed • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    15d
    ICCAUT-1: Effect of ICCAUT Strategy on Postoperative Urinary Dysfunction After Radical Rectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=230, Recruiting, The First Hospital of Jilin University | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    15d
    Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=26, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Surgery • Metastases
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation
    |
    Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)
    17d
    The association of the dietary inflammatory potential with risk of overall and site-specific cancers: A community-based longitudinal study in the UK Biobank. (PubMed, J Nutr Health Aging)
    A low-inflammatory diet is associated with decreased risk and prolonged onset time of rectal cancer and lung cancer, especially among males and individuals aged ≥60 years, and thyroid cancer among females.
    Observational data • Journal
    |
    CRP (C-reactive protein)
    17d
    PDCD4-induced oxidative stress through FGR/NF-κB axis in rectal cancer radiotherapy-induced AKI. (PubMed, Int Immunopharmacol)
    Silencing PDCD4 attenuated radiotherapy-induced AKI. Our findings suggest that PDCD4 may induce radiotherapy-induced AKI in rectal cancer by promoting FGR expression, activating the NF-κB signaling pathway, and triggering an oxidative stress response.
    Journal
    |
    KIM1 (Kidney injury molecule 1)
    19d
    Organ Preservation in Early Rectal Cancer Patients (clinicaltrials.gov)
    P2, N=19, Suspended, Fox Chase Cancer Center | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial suspension • Trial primary completion date
    |
    5-fluorouracil • leucovorin calcium
    19d
    Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial) (clinicaltrials.gov)
    P=N/A, N=154900, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    19d
    Peritoneum and Anterior Rectus Sheath Suturing and Ileostomy (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, Qilu Hospital of Shandong University
    New trial
    21d
    Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    22d
    Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer. (PubMed, Int J Colorectal Dis)
    In both age groups, MSI-H rectal cancers were more often mucinous and poorly differentiated carcinomas and had pT3-4 stage more often than MSS cancers. MSI-H rectal cancers tend to present less often with distant metastases and nodal involvement than MSS cancers only in early-onset, but not in late-onset rectal cancers. The association between MSI status and survival was not notable in this study, whether in the early-onset or late-onset groups.
    Retrospective data • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    22d
    Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) (clinicaltrials.gov)
    P=N/A, N=990, Recruiting, Washington University School of Medicine
    New trial
    23d
    Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study. (PubMed, Front Immunol)
    These traits include "CCR2 on CD14- CD16+ monocyte," "CD19 on IgD+ CD38-," "CD19 on IgD+ CD38- naive," "CD25hi CD45RA+ CD4 not Treg AC," "CD27 on unsw mem," "CD28 on CD39+ activated Treg," and "CD45 on CD4+." This study elucidates a causal link between immune cells and gastrointestinal tract cancers at various sites through genetic investigation. The findings of this research open up new perspectives and resources for exploring tumor prevention strategies and immunotherapeutic targets.
    Journal • Immune cell
    |
    CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    25d
    High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New trial • Metastases
    27d
    Identification of unique rectal cancer-specific subtypes. (PubMed, Br J Cancer)
    We conclude that RSS subtyping allows for more accurate prognosis predictions in rectal cancers than CMS subtyping and provides new insight into targetable disease pathways within these subtypes.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    MYC expression
    27d
    OBANORES: Healing of Rectal Anastomosis Sealed With a Concentrate Derived From the Patient's Blood, After Rectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=50, Completed, University of Aarhus | Recruiting --> Completed | Trial completion date: Nov 2024 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date • Surgery
    28d
    A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=255, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Jun 2025
    Enrollment closed • Trial completion date • Metastases
    |
    capecitabine • oxaliplatin
    28d
    Impact of Quality of Life in the Patients With Sleep Disturbance From Low Anterior Resection Syndrome in Advanced Rectal Cancer Patients (clinicaltrials.gov)
    P=N/A, N=100, Completed, Seoul National University Hospital | Active, not recruiting --> Completed
    Trial completion • HEOR • Metastases
    29d
    NORPPA-1: Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Tampere University Hospital
    New trial
    29d
    SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (clinicaltrials.gov)
    P2, N=13, Completed, Providence Health & Services | Active, not recruiting --> Completed
    Trial completion
    |
    oxaliplatin • Lonsurf (trifluridine/tipiracil)
    1m
    Parecoxib sodium down-regulates CXCL8-CXCR1/2 to improve inflammatory microenvironment and promote patient recovery following laparoscopic radical resection of rectal cancer (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    Parecoxib sodium can improve the inflammatory microenvironment to promote patient recovery after laparoscopic radical resection of rectal cancer possibly through a mechanism that down-regulates CXCL8-CXCR1/2 expressions in the PBMCs.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    |
    CXCL8 expression
    1m
    Clinical Validation of Multimodal Digestive Endoscopy (clinicaltrials.gov)
    P=N/A, N=20, Enrolling by invitation, Xijing Hospital of Digestive Diseases | N=12 --> 20 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment change • Trial completion date • Trial primary completion date
    1m
    RECC-EV: A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University Hospital, Bordeaux | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Liquid biopsy • Biopsy
    1m
    Pathos: Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life. (clinicaltrials.gov)
    P=N/A, N=192, Recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Trial completion date: Jan 2024 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date • HEOR
    1m
    No Surgery Trial / Two Dose-escalation Strategies (clinicaltrials.gov)
    P2/3, N=145, Recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Phase classification: P3 --> P2/3 | Trial completion date: Jan 2027 --> Jan 2030 | Trial primary completion date: Jan 2024 --> Jan 2026
    Phase classification • Trial completion date • Trial primary completion date • Surgery
    |
    capecitabine
    1m
    GI Organ Tracking Via Balloon Applicators (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Washington University School of Medicine | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    1m
    Personalized DC Vaccine for Postoperative Cancer (clinicaltrials.gov)
    P1, N=80, Recruiting, Sichuan University | Trial completion date: Jun 2023 --> Jun 2026 | Trial primary completion date: Dec 2022 --> Dec 2025
    Trial completion date • Trial primary completion date